We are delighted to inform you that NICE has recommended funding on the NHS in England for Translarna – the first ever drug to treat an underlying genetic cause of Duchenne muscular dystrophy.

Translarna would treat boys whose Duchenne is caused by a nonsense mutation, who are aged five years and over and who are still able to walk.Click here to read more.